Investigating how two receptors affect the development of Type One Diabetes
Targeting the Opposing Roles of Prostaglandin E2 Receptors, EP3 and EP4, in the Pathogenesis of Type One Diabetes
This study is looking at how two specific receptors in the body can help protect the insulin-producing cells in people with Type One Diabetes, with the hope of finding better ways to treat or even reverse the condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11055274 on NIH RePORTER |
What this research studies
This research focuses on Type One Diabetes (T1D), an autoimmune disease that leads to the destruction of insulin-producing cells in the pancreas. The study aims to explore the roles of two receptors, EP3 and EP4, which respond to a signaling molecule called Prostaglandin E2 (PGE2). By blocking the EP3 receptor and enhancing the EP4 receptor, the research seeks to promote the health and survival of pancreatic beta cells, potentially preventing or reversing the disease. The approach combines targeting the immune response with improving beta cell function, which may offer a more effective treatment strategy for T1D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type One Diabetes who are seeking new treatment options.
Not a fit: Patients with Type Two Diabetes or those without an autoimmune component to their diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reverse Type One Diabetes, improving the quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for diabetes treatment, indicating potential for success in this approach.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Burkett, Juliann B — Vanderbilt University
- Study coordinator: Burkett, Juliann B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.